Clinical Trial Drug Supply: Tirzepatide
Original notice title
Poland – Pharmaceutical products – Dostawa leku do badania klinicznego (Tirzepatyd)
Opportunity Score
Why this score?
Opportunity
0 / 100
Complexity
0 / 100
Risk factors
Submission deadline in 8 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Uniwersytecki Szpital Kliniczny nr 4 w Lublinie
- Country
- Poland
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Nov 27, 2026
AI tender analysis
Tenderwize prepares an AI analysis of this tender based on the TED notice and procurement documents: scope of work, key requirements, eligibility criteria, risks and questions for the buyer. The analysis is generated when the tender is opened.
Award Criteria
Lot 1
Buyer
Location
Lublin, POL
Website
Identifier
7122410926
Activity
Health
Lots (1)
LOT-0001
Lek do badania klinicznego (Tirzepatyd)
Przedmiotem postępowania jest dostawa leku do badania klinicznego (Tirzepatyd).
Location
Duration
Category
Award Criteria
Award details
cena
Procurement Details
- Publication date
- 17 Nov 2026
- Languages
- Polish
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 800202-2026
Documents (1)
Similar tenders
Romania – Various medicinal products – Achizitie „Medicamente eliberate pe bază de reţete compensate, gratuite sau necompensate” la unităţile din cadrul D.G.A.S.P.C. Alba
Poland – Pharmaceutical products – Sukcesywna dostawa leków w ramach programu lekowego - leczenie choroby Fabryego.
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny S01BA01 s účinnou látkou DEXAMETHASON
Portugal – Pharmaceutical products – LM 179/2026 - Aquisição de medicamentos, produtos de apoio, suplementos alimentares, produtos de higiene e cosmética, para venda aos utentes, através dos Pontos de Dispensa de Medicamentos do Laboratório Nacional do Medicamento
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX10 s účinnou látkou BENRALIZUMAB
North Macedonia – Pharmaceutical products – Lijekovi 4
Opportunity Score
Why this score?
Opportunity
0 / 100
Complexity
0 / 100
Risk factors
Submission deadline in 8 days
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications